Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind factorial study of VAA489 in essential hypertension
jRCT2080220350Phase 3
- Sponsor
- Novartis
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amlodipine + valsartan in essential hypertension, sponsored by Novartis.
02
Drugs
amlodipine + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080220350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220350.